NC Life Sciences News: United Therapeutics’ EXTEND Trial, Vogenx Russell Listing & More

Published · 9 min read · North Carolina
NC Life Sciences News: United Therapeutics’ EXTEND Trial, Vogenx Russell Listing & More

North Carolina – Regional Life Sciences Roundup – November 18, 2026

Clinical work is moving forward in North Carolina this week, and the signals reach beyond the lab.

United Therapeutics and NYU Langone Health transplanted the first investigational UThymoKidney in the EXTEND trial for end-stage renal disease. The Durham-based company is testing a xenokidney derived from a gene-edited pig, intended to train the recipient’s immune system to accept the organ. Dignify Therapeutics, also in Research Triangle Park, dosed the first healthy participant in a Phase 1 trial of DTI-117 for neurogenic bowel dysfunction, with early data expected in 2027. Humacyte submitted a supplemental biologics license application to the FDA for its acellular tissue engineered vessel in dialysis access, adding a second potential indication. These trials signal momentum in regenerative medicine and kidney care, with North Carolina firms leading the development.

The people’s side is moving early too. ProKidney promoted Farah Ali to Chief Medical Officer as the Winston-Salem company prepares for Phase 3 milestones. Sharma Oral Surgery in Charlotte transferred ownership to Dr. Rodrigo Sarmento following the founder’s retirement. Vogenx announced it will join the Russell 2000, Russell 3000, and Russell Microcap indexes in December, four months after its August IPO, broadening visibility with institutional investors as the Raleigh company advances mizagliflozin in a Phase 2b trial. SEPRO Scientific acquired Bend Genetics, establishing a West Coast diagnostics hub alongside its North Carolina lab.

The Research Triangle is building outward. Duke researchers are partnering across rural North Carolina to address health challenges, with new footprints in Vance County and community programs from East Carteret High to coastal drainage projects. ECU launched the Alliance for Brain Stimulation, bringing health sciences and engineering together to advance neurological research and treatment. Lumexa Imaging opened three new outpatient centers in November, expanding the Raleigh-based network’s reach. The North Carolina Biotechnology Center is hosting an AgTech regulatory careers panel December 9 at NC State, and the Global Forum for Plant-Based and Alternative Proteins will convene startups, strategics, and investors December 8-9 in Durham.

Financial

Tracking the capital moving through North Carolina: funding rounds, M&A activity, and investment trends shaping NC’s life sciences companies.

Vogenx joins Russell indexes as Phase 2b trial for rare metabolic condition continues

Vogenx will join the Russell 2000, Russell 3000, and Russell Microcap indexes after the S. equity markets close on December 11, 2026, according to FTSE Russell’s preliminary list published November 13. The Raleigh clinical-stage company, which completed its initial public offering in August, is advancing mizagliflozin in a Phase 2b trial for post-bariatric hypoglycemia, a condition with no FDA-approved treatment. Read More >

SEPRO Scientific Acquires Bend Genetics, Strengthening Water Testing and Diagnostics Capabilities Nationwide

SEPRO Scientific acquired Bend Genetics, a Sacramento aquatic diagnostics laboratory, establishing a West Coast hub alongside its existing North Carolina facility. The acquisition expands SEPRO’s national water testing and diagnostics capabilities, strengthening the company’s ability to serve clients across the United States. Read More >

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences granted inducement awards to new employees on November 16, 2026, under its 2021 Employment Inducement Incentive Award Plan. The awards were issued in accordance with Nasdaq Listing Rule 5635(c)(4), which permits equity grants to new hires outside of stockholder-approved plans. Read More >

Advocate Health CEO Gene Woods, wife launch charitable fund with $1M pledge

Advocate Health CEO Gene Woods and his wife launched a charitable fund with a $1 million pledge. Initial donations of $500,000 reached nine organizations, including Veterans Bridge Home and WakeMed Foundation, supporting causes in healthcare and community services. Read More >

People

Who we’re buzzing about this week: the leadership moves, board appointments, and rising names shaping the region’s life sciences community.

Sharma Oral Surgery Transfers Ownership to Dr. Rodrigo Sarmento Following Founder’s Retirement

Sharma Oral Surgery, a Charlotte oral and maxillofacial surgery practice, transferred ownership to Dr. Rodrigo Sarmento following founder Dr. Priveer Sharma’s retirement from clinical practice. Dr. Sarmento, a board-certified oral and maxillofacial surgeon who has been treating patients alongside Dr. Sharma, will assume leadership while preserving the clinical team, office location, and surgical services. Read More >

ProKidney Names Farah Ali, M.D., M.S., Chief Medical Officer

ProKidney promoted Farah Ali to Chief Medical Officer. Dr. Ali, a board-certified pediatric nephrologist with more than a decade of clinical development experience, will lead the clinical program and team as the Winston-Salem company advances the pivotal Phase 3 PROACT 1 study of rilparencel, a regenerative cell therapy for chronic kidney disease, and prepares for potential commercialization. Read More >

Workforce

The hiring activity, team expansions, and talent trends driving growth across North Carolina’s life sciences and biotech employers.

Innovation Impact Grant (IIG) Applications Open

North Carolina Biotechnology Center has opened applications for its Innovation Impact Grant program, which funds shared-use research equipment for core facilities at academic or nonprofit institutions across the state. The grants provide up to $150,000 with a required cash match, available to permanent, full-time core facility directors or faculty members. Applications are due September 30, 2026, at noon through the NCBiotech Funding Portal. Read More >

Vega Health Named to CB Insights’ 2026 Digital Health 50

CB Insights named Vega Health to its 2026 Digital Health 50, recognizing the company as one of five startups in AI infrastructure and governance. The recognition highlights companies building the technology and frameworks that support AI-driven healthcare applications. Read More >

Who’s Hiring

TOP EMPLOYER
Novartis
27OPEN ROLES
FUNCTIONAL AREAS
•  Engineering, Automation & CQV
•  Quality & Compliance
•  Facilities, Construction & Environmental Health & Safety
Open now: Scientist – Downstream Process Development – Durham, NC
See all roles ›
United Therapeutics
21OPEN ROLES
FUNCTIONAL AREAS
•  Engineering, Automation & CQV
•  Project & Program Management
•  Quality & Compliance
Open now: Procurement Analyst I, Operations – Durham, NC
See all roles ›
ViiV Healthcare
13OPEN ROLES
FUNCTIONAL AREAS
•  Commercial, Marketing & Communications
•  Medical Affairs & Scientific Communications
•  AI, Digital & Software Engineering
Open now: ViiV Healthcare (GSK) Sr. Director, Portfolio & Channel Marketing – Durham, NC
See all roles ›
View all jobs on BioBuzz

Clinical + Commercial

The latest clinical trial progress, regulatory milestones, and commercial launches from companies advancing science from the lab to the market across North Carolina.

United Therapeutics Corporation Announces First Transplant in EXTEND Clinical Trial of UThymoKidney™ in Patients with End-Stage Renal Disease

United Therapeutics and NYU Langone Health performed the first transplant in the EXTEND clinical trial of the UThymoKidney in a patient with end-stage renal disease. The investigational xenokidney, derived from a gene-edited pig with porcine thymic tissue, is designed to condition the recipient’s immune system to recognize the organ as self and reduce rejection. The Durham and Research Triangle Park-based company’s EXTEND study marks the second clinical trial in its xeno-organ manufacturing program. Read More >

Dignify Therapeutics Doses First Healthy Participant in Phase 1 Study of DTI-117 for Neurogenic Bowel Dysfunction

Dignify Therapeutics dosed the first healthy participant in a Phase 1 trial of DTI-117, an investigational on-demand intramuscular therapy for neurogenic bowel dysfunction. The NIH-funded, randomized, double-blind, placebo-controlled study will enroll up to 40 participants across five dose cohorts at the Research Triangle Park company. Preliminary topline data from the initial cohorts are expected in early 2027. Read More >

Humacyte Submits Supplemental Biologics License Application to FDA for the Acellular Tissue Engineered Vessel in Dialysis Access

Humacyte submitted a supplemental biologics license application to the FDA seeking approval for its acellular tissue engineered vessel in arteriovenous access for hemodialysis in patients with end-stage kidney disease. The Durham company’s submission, supported by results from three Phase 3 studies, seeks to add dialysis access as a second approved indication for the ATEV. Read More >

Ecosystem

The partnerships, programs, and policy moves building North Carolina’s life sciences infrastructure, and the organizations driving it forward.

RedHill Biopharma Highlights Strategic Transformation and Expanded Commercial Growth Strategy

RedHill Biopharma highlighted its strategic transformation and expanded commercial growth strategy in a virtual investor segment on November 17. Chief Business Officer Guy Goldberg discussed the company’s evolution into a scalable commercial-stage business following strategic transactions, including the divestiture of Talicia, and opportunities to drive growth across its expanded gastrointestinal portfolio. Read More >

BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO

BioCryst presented two real-world studies at the ACAAI 2026 Annual Scientific Meeting demonstrating reductions in healthcare resource utilization in hereditary angioedema patients who initiated or switched to ORLADEYO from another prophylactic therapy. The data showed reduced angioedema-related medical visits after patients began treatment with berotralstat. Read More >

Lumexa Imaging Opens Three New Imaging Centers in November

Lumexa Imaging opened three new outpatient imaging centers in November. The Raleigh-based company, one of the nation’s largest outpatient imaging providers, continues to expand its network of diagnostic facilities across the region. Read More >

Other [Good] Reads

Editor’s picks from across the web: the stories, videos, and podcasts shaping the conversation in NC biotech and life sciences this week.

UNC Lineberger physicians spotlight research to fine-tune breast cancer care

UNC Lineberger Comprehensive Cancer Center physicians Lisa Carey and Yara Abdou published a commentary in the Journal of Clinical Oncology reviewing how tests that examine gene activity in breast tumors can help doctors match treatment to individual patients. The article discusses recent findings on which patients with early-stage hormone receptor-positive HER2-negative breast cancer benefit from chemotherapy and which may safely avoid it. Read More >

ECU researchers put brain science to work for patients

East Carolina University launched the Alliance for Brain Stimulation, bringing health sciences researchers and technologists together to advance brain research. The alliance is using tools such as transcranial magnetic stimulation, MRI, EEG, functional near-infrared spectroscopy, and eye tracking to study how the brain works while training the next generation of health professionals. Read More >

Research With Reach: How Duke Partners on Rural Health

Duke researchers are partnering with community organizations across North Carolina to address rural health challenges. The collaborations include a new healthcare and research footprint in Vance County and work with groups such as East Carteret High School’s National Art Honors Society on community health initiatives, demonstrating Duke’s commitment to improving health outcomes in underserved areas. Read More >

Molecular measurement hits fast forward

Scott Mellors, Michael Ramsey, Will Thompson, and James Campbell are building Move Analytical, a company designed to make molecular measurement tools faster, cheaper, and easier to access. The team previously worked together at 908 Devices, where technology from Ramsey’s UNC-Chapel Hill lab helped build a product, and they are now applying that experience to advance metabolomics for labs entering the field. Read More >

On the Calendar

A few of the upcoming events, conferences, and networking opportunities across North Carolina’s life sciences ecosystem that you don’t want to miss.

9th International Conference on Microbiome Engineering

Tuesday-Thursday, December 1-3 · Raleigh-Durham, North Carolina

Hosted by Society for Biological Engineering | Register Now >

AgTech Regulatory: "Careers in Regulatory Science & Affairs Panel"

Wednesday, December 9 · 3:30 PM–6 PM · Department of Crop and Soil Sciences, NC State University, Raleigh, NC

Hosted by North Carolina Biotechnology Center | Register Now >

2nd Annual Global Forum for Plant-Based and Alternative Protein Conference

Wednesday, December 9 · 8:30 AM–6:30 PM · First Flight Venture Center, Durham, NC

Hosted by Global Forum for Plant-based and Alternative Proteins | Register Now >

See all events on BioBuzz

Did we miss something!? Drop us a line →

Stay connected to North Carolina’s life sciences.

Explore companies →   Browse jobs →   See events →   Read more →

Get Connected →